Capital Asset Advisory Services LLC Increases Position in Danaher Corporation $DHR

Capital Asset Advisory Services LLC boosted its position in Danaher Corporation (NYSE:DHR) by 23.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 14,525 shares of the conglomerate’s stock after acquiring an additional 2,739 shares during the period. Capital Asset Advisory Services LLC’s holdings in Danaher were worth $2,880,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Praxis Investment Management Inc. increased its stake in Danaher by 2.0% in the third quarter. Praxis Investment Management Inc. now owns 29,962 shares of the conglomerate’s stock valued at $5,940,000 after purchasing an additional 588 shares during the last quarter. Caldwell Trust Co purchased a new stake in Danaher in the 2nd quarter valued at about $949,000. Canal Capital Management LLC increased its stake in shares of Danaher by 9.4% during the 2nd quarter. Canal Capital Management LLC now owns 16,621 shares of the conglomerate’s stock valued at $3,283,000 after acquiring an additional 1,435 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Danaher by 10.6% during the 2nd quarter. Valeo Financial Advisors LLC now owns 12,918 shares of the conglomerate’s stock worth $2,552,000 after acquiring an additional 1,243 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in shares of Danaher by 43.6% during the 2nd quarter. Osaic Holdings Inc. now owns 75,269 shares of the conglomerate’s stock worth $15,055,000 after acquiring an additional 22,869 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Bank of America lowered their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Barclays increased their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. The Goldman Sachs Group began coverage on Danaher in a research report on Tuesday, December 9th. They set a “buy” rating and a $265.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $247.21.

Danaher Price Performance

DHR stock opened at $228.57 on Tuesday. The stock has a 50-day simple moving average of $218.85 and a 200-day simple moving average of $206.17. The firm has a market cap of $161.45 billion, a P/E ratio of 47.13, a price-to-earnings-growth ratio of 4.39 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the company earned $1.71 earnings per share. Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is currently 26.39%.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 3,298 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last ninety days. Insiders own 11.20% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.